Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2018-05-21 Capital/Financing Update
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 16, 2018, reporting the entry into a material definitive agreement—a loan and security agreement providing a $50 million term loan facility. The content focuses on the terms of the loan, interest rates, covenants, and default conditions. There are no financial statements or comprehensive financial performance data included. The document is a current report disclosing a significant financing event, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (8810 characters) is sufficient to contain substantive details, confirming it is not a mere announcement or certification. Hence, the classification is CAP with high confidence.
2018-05-21 English
10-Q
Interim / Quarterly Report Q1 2018
2018-05-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2018, reporting the company's financial results for the quarter ended March 31, 2018. It specifically states that the full text of the press release is furnished as an exhibit and that the information is not considered filed under the Securities Exchange Act. The document is short (3239 characters) and primarily serves as an announcement of the earnings release rather than containing the full financial results itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results highlights, even though the full details are in the attached press release. The document is not the full quarterly report (IR) nor a regulatory filing of other types. Confidence is high due to clear identification of the earnings announcement and the nature of the Form 8-K item 2.02 disclosure.
2018-05-08 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-26 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about the Annual Meeting of Stockholders, nominees for director positions, and ratification of the auditor. It also provides instructions on how to access the full proxy materials and vote. The document is not the proxy statement itself but additional materials related to the proxy solicitation process. The presence of the term 'definitive additional materials' and the nature of the content indicate this is a Proxy Solicitation & Information Statement filing. The document length is 4668 characters, which is consistent with a detailed proxy solicitation document rather than a brief announcement or a full annual report. Therefore, the correct classification is DEF 14A (Remuneration Information) since Schedule 14A filings typically include executive compensation and proxy solicitation information, but given the content focuses on proxy materials and director nominations, the best fit is Proxy Solicitation & Information Statement (PSI). However, since the document is titled DEFA14A and includes proxy materials, the most precise classification is DEF 14A.
2018-04-26 English
Regulatory Filings 2018
Regulatory Filings
2018-04-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.